Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead candidate in CALMA, a randomized double-blind placebo-controlled Phase 2 trial; 146-patient enrollment target reached June 2026, over-enrollment and follow-up ongoing; database lock, site closeout and topline analysis expected next (no date stated). Phase 1 safety completed. Preclinical data suggest activity against AD pathology pathways.
TGR-63
Preclinical · Active
Target amyloid-beta (Aβ)
Indications
Alzheimer's disease(Preclinical)
Status note Earlier-stage candidate targeting AD mechanisms, in preclinical evaluation; no target, modality or indication detail stated.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.